WuXi AppTec : Testing - 2022 Investor Day

2 0 2 2 Wu X i A p p Te c I n v e s t o r D a y

WuXi Testing:

End-to-End Testing Platform

Steve Yang, Ph.D.

Co-CEO

WuXi Testing: End-to-End Testing Platform for All Modalities

Discovery	Pre-Clinical

Small Molecule

Biologics, Cell / Gene Therapy

WuXi Chemistry & WuXi Biologics

Pre-Clinical Testing	WuXi
	Testing
Clinical Testing

Commercial

Clinical

• WIND (WuXi IND)
• DMPK
• Toxicology
• Bioanalysis
• Medical Device Testing
• Clinical CRO
• Clinical SMO

2

WuXi Testing: A Global Platform from Preclinical to Clinical

Employees				Clients1				Projects2
9,300+				2,200+				8,800+

•	3,500+	Pre-clinical	•	2,100+ Pre-clinical	•	5,500+	Pre-clinical
•	5,800+	Clinical	•	800+ Clinical		(Including 140 WIND)
					•	3,300+	Clinical

Note: 1. Active client with PO award

2. Active projects with PO award ( Multiple projects may cover single molecule) Data from: Jul 2021 to Jun 2022

3

WuXi Testing: Robust Track Record & Growth Forecast

+29%

2018A

2019A

2020A

2021A

H2

H1

2022E

4

WuXi Testing: Business Performance by Division

Lab Testing Business

+39%

H2

				H1
2018A	2019A	2020A	2021A	2022E

SMO Business

				+23%
				H2
				H1
2018A	2019A	2020A	2021A	2022E

WuXi Clinical Business

				-8%
				H2
				H1
2018A	2019A	2020A	2021A	2022E

5